TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05552755: Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

Sponsor: Recursion Pharmaceuticals Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 67 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,693,200

Rescue Site Savings

+$1,128,800

Unlock Full NCT05552755 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05552755 Rescue Dossier →